Investigators enrolled 54 men with high‑volume metastatic hormone‑naive prostate cancer (mHNPC) who were starting androgen deprivation therapy. All patients received a two‑cycle lead‑in of enzalutamide before randomization. The trial used a 1:2 allocation; the report lists 17 patients randomized to enzalutamide alone and 37 to enzalutamide plus talazoparib. The source did not provide additional stratification details in the abstract. The study team defined the primary endpoint as the proportion of patients achieving PSA <0.2 ng ml−1 at 12 months; that preplanned threshold governed efficacy determination. ClinicalTrials.gov identifier reported: NCT04332744.
The combination arm met the study's prespecified efficacy threshold. Data indicated a 73% PSA <0.2 ng ml−1 response rate at 12 months in patients who received talazoparib plus enzalutamide (95% CI = 56–86%), and the study team reported P < 0.001 versus the predefined efficacy boundary. By contrast, the enzalutamide‑alone arm had a 12‑month PSA <0.2 rate of 64.7% (95% CI = 38–86%). An exploratory, between‑arm comparison produced P = 0.54, which the authors reported as not demonstrating a statistically significant difference between arms in that comparison. The abstract did not report additional efficacy endpoints such as radiographic progression‑free survival or overall survival within the source text provided here; those outcomes, if collected, were not summarized in the abstract excerpt.
The safety signal differed markedly between arms. Grade ≥3 adverse events occurred in 68% of patients receiving the combination versus 35% with enzalutamide alone. The most frequent severe toxicity in the combination arm was anemia, reported in 41% of those patients. The authors reported two fatal therapy‑emergent myeloid neoplasms in the combination arm; both occurred in patients described as having underlying genomic susceptibility. The source reported those events explicitly. The abstract did not provide granular timelines for onset, management strategies, or detailed hematologic laboratory trajectories; such granular safety data were not reported in the abstract excerpt.
Paired tumor biopsies were collected at baseline and after the enzalutamide lead‑in, and the study team analyzed transcriptional programs. Data indicated marked tumor transcriptional reprogramming following androgen receptor (AR) inhibition. Specifically, the cohort showed suppression of proliferation‑associated gene expression programs and downregulation of homologous recombination repair (HRR)‑related gene expression. Despite this gene expression suppression, the investigators reported that there was no functional impairment of homologous recombination activity. The source did not detail the assays used to assess functional HRR competence in the abstract, nor did it provide per‑patient genomic breakdowns or biomarker subgroups in the excerpt provided here.
The authors observed that talazoparib plus enzalutamide produced clinical activity in patients with high‑volume mHNPC, meeting the trial's primary endpoint. At the same time, the combination carried a higher burden of severe adverse events and was linked to two fatal therapy‑emergent myeloid neoplasms in patients with reported genomic susceptibility. In the dataset presented, the combination did not establish a clear additional clinical benefit over enzalutamide alone in this biomarker‑unselected population; the exploratory between‑arm comparison did not show a statistically significant difference (P = 0.54). The report described suppression of HRR‑related gene expression after AR inhibition but no observable loss of functional homologous recombination activity based on the analyses the authors reported.
Limitations documented in the source include the small randomized sample size and the absence—within the abstract excerpt provided here—of detailed subgroup efficacy by HRR alteration status, comprehensive radiographic or survival endpoints, and the specific methods used to assess functional HRR. The source did not report those methodological or subgroup details in the abstract. Outstanding clinical questions that remain, as framed by the data reported, include whether a biomarker‑selected population (for example, patients with deleterious HRR alterations) might derive clearer incremental benefit from adding a PARP inhibitor to upfront AR‑directed therapy, and how to mitigate hematologic risks when combining potent PARP inhibition with AR pathway inhibitors. The trial's identifier (NCT04332744) is provided for readers seeking the full protocol and complete dataset; that registry may contain further methodological and outcome details beyond the abstract.